Breaking News
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% Upgrade now
Close

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Gilead's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
61.69 -1.38    -2.19%
30/09 - Closed. Currency in USD ( Disclaimer )
After Hours
61.78
+0.09
+0.15%
30/09
  • Volume: 8,777,150
  • Bid/Ask: 61.70 / 62.02
  • Day's Range: 61.61 - 63.58
Type:  Equity
Market:  United States
Gilead 61.69 -1.38 -2.19%

GILD Financial Summary

 
See below for an overview of the Gilead financial reports. To explore the data further, select a tab to navigate onto a specific report page. Choose to view either annual or quarterly report data.

Gilead Sciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 6,260 million compared to USD 6,217 million a year ago. Net income was USD 1,144 million compared to USD 1,522 million a year ago. Basic earnings per share from continuing operations was USD 0.91 compared to USD 1.21 a year ago. Diluted earnings per share from continuing operations was USD 0.91 compared to USD 1.21 a year ago.For the six months, revenue was USD 12,850 million compared to USD 12,640 million a year ago. Net income was USD 1,163 million compared to USD 3,251 million a year ago. Basic earnings per share from continuing operations was USD 0.93 compared to USD 2.59 a year ago. Diluted earnings per share from continuing operations was USD 0.92 compared to USD 2.58 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

GILD Income Statement

Gross margin TTM 79.5%
Operating margin TTM 40.36%
Net Profit margin TTM 15.04%
Return on Investment TTM 16.6%
 Total Revenue  Net Income
Period Ending: Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021
Total Revenue 6260 6590 7244 7421
Gross Profit 4818 5166 4617 6198
Operating Income 2359 197 940 3842
Net Income 1144 19 382 2592

GILD Balance Sheet

Quick Ratio MRQ 1.11
Current Ratio MRQ 1.43
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 129.55%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021
Total Assets 62870 63080 67952 67098
Total Liabilities 42655 43153 46883 45628
Total Equity 20215 19927 21069 21470

GILD Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  19.54%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021
Period Length: 0 Months 3 Months 12 Months 0 Months
Cash From Operating Activities 1802 1840 11384 8179
Cash From Investing Activities -308 -1070 -3131 -2853
Cash From Financing Activities -1003 -1794 -8877 -6935
Net Change in Cash 443 -1042 -659 -1635
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GILD Comments

Write your thoughts about Gilead Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oc Masai
Oc Masai Apr 27, 2021 7:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good job GILD. bullish move forward
Ashraf Elgendy
Ashraf Elgendy Mar 07, 2021 13:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
RM RM
RM RM Mar 01, 2021 21:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Up Again
Ken Laing
Ken Laing Oct 23, 2020 18:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to load up before the big rise coming next week
Iggy Maldon
Iggy Maldon Jul 30, 2020 20:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Classic pump n’ dump. What a shambles
RM RM
RM RM May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will reach above 95
Chili Daug
Chili Daug May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when? hahah
SAGAR AGARWAL
SAGAR AGARWAL May 15, 2020 14:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good time to accumulate.
Khizer Malik
Khizer Malik May 14, 2020 11:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
Willy Chin
Willy Chin Apr 23, 2020 18:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
High chance to be trading above 90, good long stock
Viktor Veselý
Viktor Veselý Apr 12, 2020 7:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email